How many drugs treat Depressive disorder?

Drug Landscape tracks 10 marketed treatments for Depressive disorder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/depressive-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Depressive disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Depressive disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Depressive disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Spravato	ESKETAMINE	Johnson & Johnson	esketamine		2019-01-01
Celexa	CITALOPRAM	AbbVie	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Zoloft	sertraline	Pfizer Inc.	SSRI (Selective serotonin reuptake inhibitor)	Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A	1991-12-30
Prozac	fluoxetine	Eli Lilly and Company	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Amoxan	AMOXAPINE	Pfizer	Tricyclic Antidepressant [EPC]	5-hydroxytryptamine receptor 2A	1980-01-01
Surmontil	TRIMIPRAMINE	Teva Womens	Tricyclic Antidepressant	Histamine H1 receptor	1979-01-01
Norpramin	DESIPRAMINE	Validus Pharms	Tricyclic Antidepressant	Sodium-dependent dopamine transporter	1964-01-01
Nardil	PHENELZINE	Pfizer	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01
Nardil	Phenelzine Sulfate	Pfizer	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 19 drugs in Depressive disorder
Pfizer · 3 drugs in Depressive disorder
Ain Shams University · 1 drug in Depressive disorder
AstraZeneca · 1 drug in Depressive disorder
Boehringer Ingelheim · 1 drug in Depressive disorder
Eli Lilly and Company · 1 drug in Depressive disorder
GSK (GlaxoSmithKline) · 1 drug in Depressive disorder
Johnson & Johnson · 1 drug in Depressive disorder
Mahatma Gandhi Institute of Medical Sciences · 1 drug in Depressive disorder
Mclean Hospital · 1 drug in Depressive disorder
Pfizer Inc. · 1 drug in Depressive disorder
Poznan University of Medical Sciences · 1 drug in Depressive disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Depressive disorder:

Cite this brief

Drug Landscape (2026). Depressive disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/depressive-disorder. Accessed 2026-06-10.

Depressive disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing